We serve Chemical Name:(4S)-2α,3β-Dihydroxy-D:C-friedo-B’:A’-neogammacer-9(11)-en-23-oic acid CAS:35591-41-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4S)-2α,3β-Dihydroxy-D:C-friedo-B’:A’-neogammacer-9(11)-en-23-oic acid
CAS.NO:35591-41-4
Synonyms:Retigeric acid A
Molecular Formula:C30H48O4
Molecular Weight:472.70000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:572ºC at 760 mmHg
Density:1.14
Index of Refraction:
PSA:77.76000
Exact Mass:472.35500
LogP:6.06030
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Retigeric acid A chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Retigeric acid A physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Retigeric acid A Use and application,Retigeric acid A technical grade,usp/ep/jp grade.
Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. (4S)-2α,3β-Dihydroxy-D:C-friedo-B’:A’-neogammacer-9(11)-en-23-oic acid manufacturer The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter. (4S)-2α,3β-Dihydroxy-D:C-friedo-B’:A’-neogammacer-9(11)-en-23-oic acid supplier As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. (4S)-2α,3β-Dihydroxy-D:C-friedo-B’:A’-neogammacer-9(11)-en-23-oic acid vendor The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter. (4S)-2α,3β-Dihydroxy-D:C-friedo-B’:A’-neogammacer-9(11)-en-23-oic acid factory Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.
